Personal CFO Solutions LLC Has $1.81 Million Stake in Novartis AG $NVS

Personal CFO Solutions LLC lifted its position in shares of Novartis AG (NYSE:NVS) by 280.3% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 11,831 shares of the company’s stock after acquiring an additional 8,720 shares during the quarter. Personal CFO Solutions LLC’s holdings in Novartis were worth $1,807,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its stake in Novartis by 18.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 537,543 shares of the company’s stock worth $68,935,000 after acquiring an additional 82,226 shares during the last quarter. BXM Wealth LLC increased its stake in Novartis by 726.9% in the fourth quarter. BXM Wealth LLC now owns 42,817 shares of the company’s stock valued at $5,903,000 after purchasing an additional 37,639 shares in the last quarter. Spire Wealth Management raised its holdings in Novartis by 2,561.0% in the fourth quarter. Spire Wealth Management now owns 38,983 shares of the company’s stock worth $5,375,000 after purchasing an additional 37,518 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in Novartis by 14.4% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 113,737 shares of the company’s stock worth $15,681,000 after purchasing an additional 14,352 shares during the period. Finally, HF Advisory Group LLC boosted its position in shares of Novartis by 401.0% during the fourth quarter. HF Advisory Group LLC now owns 54,741 shares of the company’s stock worth $7,547,000 after purchasing an additional 43,814 shares in the last quarter. Institutional investors and hedge funds own 13.12% of the company’s stock.

Novartis Stock Down 1.1%

Novartis stock opened at $155.28 on Thursday. The company has a debt-to-equity ratio of 0.96, a current ratio of 0.85 and a quick ratio of 0.65. The company’s 50-day moving average is $150.45 and its 200-day moving average is $150.96. The firm has a market capitalization of $296.30 billion, a PE ratio of 22.25, a P/E/G ratio of 2.70 and a beta of 0.45. Novartis AG has a fifty-two week low of $112.34 and a fifty-two week high of $170.46.

Novartis (NYSE:NVS) last issued its earnings results on Monday, April 27th. The company reported $1.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.11 by ($0.12). Novartis had a net margin of 24.87% and a return on equity of 38.82%. The firm had revenue of $13.52 billion during the quarter, compared to analyst estimates of $13.44 billion. During the same quarter last year, the business posted $2.28 earnings per share. The company’s revenue for the quarter was down .9% on a year-over-year basis. Sell-side analysts anticipate that Novartis AG will post 8.77 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Weiss Ratings cut Novartis from a “buy (a-)” rating to a “buy (b)” rating in a research note on Wednesday, April 29th. Sanford C. Bernstein upgraded shares of Novartis to a “hold” rating in a report on Thursday, March 19th. Argus raised shares of Novartis from a “hold” rating to a “buy” rating and set a $180.00 price objective for the company in a research report on Wednesday, March 11th. Finally, Morgan Stanley raised their price objective on shares of Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a report on Thursday, March 26th. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $141.20.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.